Hubbry Logo
MyoglobinMyoglobinMain
Open search
Myoglobin
Community hub
Myoglobin
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Myoglobin
Myoglobin
Myoglobin
View on Wikipedia
from Wikipedia

MB
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesMB, PVALB, myoglobgin, myoglobin, Myoglobin
External IDsOMIM: 160000; MGI: 96922; HomoloGene: 3916; GeneCards: MB; OMA:MB - orthologs
Orthologs
SpeciesHumanMouse
Entrez

4151

17189

Ensembl

ENSG00000198125

ENSMUSG00000018893

UniProt

P02144

P04247

RefSeq (mRNA)

NM_005368
NM_203377
NM_203378
NM_001362846

NM_001164047
NM_001164048
NM_013593

RefSeq (protein)

NP_001157519
NP_001157520
NP_038621

Location (UCSC)Chr 22: 35.61 – 35.64 MbChr 15: 76.9 – 76.93 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Myoglobin (symbol Mb or MB) is an iron- and oxygen-binding protein found in the cardiac and skeletal muscle tissue of vertebrates in general and in almost all mammals.[5][6][7][8][9] Myoglobin is distantly related to hemoglobin. Compared to hemoglobin, myoglobin has a higher affinity for oxygen and does not have cooperative binding with oxygen like hemoglobin does.[8][10] Myoglobin consists of non-polar amino acids at the core of the globulin, where the heme group is non-covalently bounded with the surrounding polypeptide of myoglobin. In humans, myoglobin is found in the bloodstream only after muscle injury.[11][12][13]

High concentrations of myoglobin in muscle cells allow organisms to hold their breath for a longer period of time. Diving mammals such as whales and seals have muscles with particularly high abundance of myoglobin.[13] Myoglobin is found in Type I muscle, Type II A, and Type II B; although many older texts describe myoglobin as not found in smooth muscle, this has proved erroneous: there is also myoglobin in smooth muscle cells.[14]

Myoglobin was the first protein to have its three-dimensional structure revealed by X-ray crystallography.[15] This achievement was reported in 1958 by John Kendrew and associates.[16] For this discovery, Kendrew shared the 1962 Nobel Prize in Chemistry with Max Perutz.[17][18] Despite being one of the most studied proteins in biology, its physiological function is not yet conclusively established: mice genetically engineered to lack myoglobin can be viable and fertile, but show many cellular and physiological adaptations to overcome the loss. Through observing these changes in myoglobin-depleted mice, it is hypothesised that myoglobin function relates to increased oxygen transport to muscle, and to oxygen storage; as well, it serves as a scavenger of reactive oxygen species.[19]

In humans, myoglobin is encoded by the MB gene.[20]

Myoglobin can take the forms oxymyoglobin (MbO2), carboxymyoglobin (MbCO), and metmyoglobin (met-Mb), analogously to hemoglobin taking the forms oxyhemoglobin (HbO2), carboxyhemoglobin (HbCO), and methemoglobin (met-Hb).[21]

Differences from hemoglobin

[edit]

Like hemoglobin, myoglobin is a cytoplasmic protein that binds oxygen on a heme group. It harbors only one globulin group, whereas hemoglobin has four. Although its heme group is identical to those in Hb, Mb has a higher affinity for oxygen than does hemoglobin but fewer total oxygen-storage capacities. Research suggests that myoglobin facilitates oxygen diffusion down a gradient, enhancing oxygen transport in mitochondria.[22]

Role in cuisine

[edit]

Myoglobin contains hemes, pigments responsible for the color of red meat. The color that meat takes is partly determined by the degree of oxidation of the myoglobin. In fresh meat the iron atom is in the ferrous (+2) oxidation state bound to an oxygen molecule (O2). Meat cooked well done is brown because the iron atom is now in the ferric (+3) oxidation state, having lost an electron. If meat has been exposed to nitrites, it will remain pink, because the iron atom is bound to NO, nitric oxide (true of, e.g., corned beef or cured hams). Grilled meats can also take on a reddish pink "smoke ring" that comes from the heme center binding to carbon monoxide.[23] Raw meat packed in a carbon monoxide atmosphere also shows this same pink "smoke ring" due to the same principles. Notably, the surface of this raw meat also displays the pink color, which is usually associated in consumers' minds with fresh meat. This artificially induced pink color can persist, reportedly up to one year.[24] Hormel and Cargill (meat processing companies in the US) are both reported to use this meat-packing process, and meat treated this way has been in the consumer market since 2003.[25] If fresh meat is left to an environment where the redox potential is high, oxymyoglobin will eventually turn into metmyoglobin (Fe+3) and the meat will turn into dark red naturally.[26]

Meat alternatives have used various ways to recreate the "meaty" taste associated with myoglobin. Impossible Foods uses leghemoglobin, a heme-containing globin from soy root nodule, produced as a recombinant protein in Komagataella ("Pichia pastoris") yeast.[27][28] Motif FoodWorks produces a recombinant bovine myoglobin using Komagataella yeast,[29] considered GRAS by the FDA.[30] Moolec Science has engineered a soybean that produces porcine myoglobin in its seeds called "Piggy Sooy"; it was approved by the USDA in April 2024.[31]

Role in disease

[edit]

Myoglobin is released from damaged muscle tissue, which contain very high concentrations of myoglobin.[32] The released myoglobin enters the bloodstream, where high levels may indicate rhabdomyolysis. The myoglobin is filtered by the kidneys, but is toxic to the renal tubular epithelium and so may cause acute kidney injury.[33] It is not the myoglobin itself that is toxic (it is a protoxin), but the ferrihemate portion that is dissociated from myoglobin in acidic environments (e.g., acidic urine, lysosomes).[citation needed]

Myoglobin is a sensitive marker for muscle injury, making it a potential marker for heart attack in patients with chest pain.[34] However, elevated myoglobin has low specificity for acute myocardial infarction (AMI) and thus CK-MB, cardiac troponin, ECG, and clinical signs should be taken into account to make the diagnosis.[35]

Structure and bonding

[edit]

Myoglobin belongs to the globin superfamily of proteins, and as with other globins, consists of eight alpha helices connected by loops. Human myoglobin contains 154 amino acids.[36]

Myoglobin contains a porphyrin ring with an iron at its center. A proximal histidine group (His-93) is attached directly to iron, and a distal histidine group (His-64) hovers near the opposite face.[36] The distal imidazole is not bonded to the iron, but is available to interact with the substrate O2. This interaction encourages the binding of O2, but not carbon monoxide (CO), which still binds about 240× more strongly than O2.[citation needed]

The binding of O2 causes substantial structural change at the Fe center, which shrinks in radius and moves into the center of N4 pocket. O2-binding induces "spin-pairing": the five-coordinate ferrous deoxy form is high spin and the six coordinate oxy form is low spin and diamagnetic.[citation needed]

  • Molecular orbital description of Fe-O2 interaction in myoglobin.[37]
    Molecular orbital description of Fe-O2 interaction in myoglobin.[37]
  • This is an image of an oxygenated myoglobin molecule. The image shows the structural change when oxygen is bound to the iron atom of the heme prosthetic group. The oxygen atoms are colored in green, the iron atom is colored in red, and the heme group is colored in blue.
    This is an image of an oxygenated myoglobin molecule. The image shows the structural change when oxygen is bound to the iron atom of the heme prosthetic group. The oxygen atoms are colored in green, the iron atom is colored in red, and the heme group is colored in blue.
  • Myoglobin
    Myoglobin

Synthetic analogues

[edit]

Many models of myoglobin have been synthesized as part of a broad interest in transition metal dioxygen complexes. A well known example is the picket fence porphyrin, which consists of a ferrous complex of a sterically bulky derivative of tetraphenylporphyrin.[38] In the presence of an imidazole ligand, this ferrous complex reversibly binds O2. The O2 substrate adopts a bent geometry, occupying the sixth position of the iron center. A key property of this model is the slow formation of the μ-oxo dimer, which is an inactive diferric state. In nature, such deactivation pathways are suppressed by protein matrix that prevents close approach of the Fe-porphyrin assemblies.[39]

A picket-fence porphyrin complex of Fe, with axial coordination sites occupied by methylimidazole (green) and dioxygen. The R groups flank the O2-binding site.

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Myoglobin

View on Grokipedia
from Grokipedia
Myoglobin is a monomeric heme-containing protein predominantly expressed in skeletal and cardiac muscle cells, where it reversibly binds oxygen to store it intracellularly and facilitate its diffusion to mitochondria during periods of high metabolic demand. Encoded by the MB gene located on human chromosome 22q12-13, myoglobin consists of a single polypeptide chain of 153 amino acids folded into eight alpha-helices that enclose a heme prosthetic group, enabling selective oxygen binding at the iron atom within the porphyrin ring. The three-dimensional structure of myoglobin, determined by John Kendrew in 1959 using X-ray crystallography on sperm whale myoglobin, was the first atomic-resolution model of a protein, revealing the principles of globular protein folding and ligand binding that underpin much of modern structural biology. This breakthrough earned Kendrew the 1962 Nobel Prize in Chemistry, shared with Max Perutz for their work on globular proteins. Beyond oxygen storage, myoglobin modulates intracellular oxygen gradients, scavenges nitric oxide to prevent interference with respiration, and may catalyze reactions involving reactive oxygen species, highlighting its multifaceted role in muscle physiology. Its oxygen dissociation curve, with a higher affinity than hemoglobin, ensures efficient release under hypoxic conditions within contracting muscle fibers.

History and Discovery

Early Identification and Isolation

The muscle pigment responsible for the red color of skeletal and cardiac tissues was first spectroscopically detected by Charles A. MacMunn in 1886, who distinguished it from hemoglobin in blood and named it myohaematin based on its absorption bands in muscle extracts. MacMunn's observations, made using a spectroscope on tissue samples from various animals, revealed characteristic bands at wavelengths corresponding to reduced and oxidized forms, but his work was initially dismissed by contemporaries like Hoppe-Seyler as artifacts or hemoglobin derivatives. In 1897, K. A. H. Mörner conducted more precise spectroscopic analyses on extracted muscle pigments from mammals, confirming a distinct heme-containing protein separate from hemoglobin, which he termed myohaemoglobin (later myochrome) due to its unique spectral properties, including sharper absorption bands in the Soret region. Mörner's extraction involved acidifying minced muscle tissue to release the pigment, followed by salting out with ammonium sulfate, enabling differentiation via reduced oxygen affinity compared to blood hemoglobin. Advances in purification occurred in the early 1930s, with Hugo Theorell developing methods to isolate myoglobin from horse heart muscle by sequential precipitation with ammonium sulfate at specific saturations (around 60-80%), acidification to pH 6-7, and crystallization from concentrated solutions at low temperatures. This yielded pure, crystalline myoglobin with a molecular weight determined via osmotic pressure and early ultracentrifugation studies at approximately 17,000-17,500 Da, establishing its monomeric structure in contrast to hemoglobin's tetrameric assembly of ~68,000 Da. Theorell's preparations demonstrated reversible oxygenation without the cooperative binding seen in hemoglobin, confirming myoglobin's role as a distinct oxygen-binding protein through solubility and sedimentation analyses.

Structural Elucidation by X-ray Crystallography

John C. Kendrew and his team at the Medical Research Council Laboratory of Molecular Biology initiated X-ray crystallographic studies on sperm whale (Physeter catodon) myoglobin in the late 1940s, selecting this protein due to its ability to form well-diffracting crystals suitable for structural analysis. By the mid-1950s, they had collected extensive diffraction data from type A monoclinic crystals grown in ammonium sulfate solutions. The primary challenge was solving the phase problem, addressed through the multiple isomorphous replacement method using heavy-atom derivatives, such as p-chloromercuribenzoate for mercury labeling and potassium platinum chloride for platinum substitution at specific cysteine and histidine residues. These derivatives provided phase information by altering scattering amplitudes without significantly disrupting crystal isomorphism. In 1958, computational analysis of the three-dimensional diffraction data, aided by early electronic computers like the EDSAC, produced a low-resolution electron density map at 6 Å, disclosing the protein's overall fold as a compact bundle of eight alpha-helices enclosing a central cavity. This map marked the first visualization of a protein's tertiary structure, revealing rod-like densities consistent with alpha-helices and validating Linus Pauling's 1951 theoretical model of the right-handed alpha-helix as a prevalent secondary structure in proteins. The helical content exceeded initial expectations, comprising about 75% of the polypeptide chain, and demonstrated the feasibility of helical folding in globular proteins despite earlier skepticism regarding its stability in aqueous environments. Subsequent refinement, incorporating higher-resolution data collected via improved instrumentation, yielded a 2 Å atomic model in 1960, enabling precise tracing of the 153-residue chain, placement of side chains, and localization of the heme group within the helical pocket. This high-resolution structure elucidated key structural features, such as the proximal histidine coordination to the heme iron and the distal pocket geometry, foundational for understanding oxygen binding. Kendrew's achievements, representing the inaugural atomic-resolution determination of a protein structure, earned him the 1962 Nobel Prize in Chemistry, shared with Max Perutz for complementary work on hemoglobin.

Molecular Structure and Properties

Primary Sequence and Folding

Myoglobin's primary structure in humans comprises a single polypeptide chain of 154 amino acids. Approximately half of these residues possess nonpolar side chains, which cluster internally to drive folding via hydrophobic interactions, while polar and charged residues predominate on the exterior for aqueous solubility. The sequence exhibits high conservation across vertebrate species, reflecting functional constraints on the oxygen-binding pocket and overall fold; for instance, myoglobins from elephant and sperm whale share 81% amino acid identity. The protein folds into a compact globular tertiary structure dominated by alpha-helical secondary elements, comprising eight helices designated A through H and spanning about 75% of the chain length. These helices are linked by short loops, with the arrangement forming a characteristic "globin fold" stabilized primarily by a central hydrophobic core of nonpolar residues that minimizes solvent exposure and entropy loss upon folding. Surface-exposed polar residues facilitate solubility in the cytoplasmic milieu of muscle cells, while intra-helical hydrogen bonds and packing of the core provide rigidity against unfolding. This architecture emerges from the primary sequence through cooperative hydrophobic collapse, as evidenced by folding studies showing rapid formation of helical intermediates prior to core packing. The conserved helical bundle creates two interconnected hydrophobic networks, one encompassing helices A, B, E, and H, and another involving C, D, F, and G, which collectively resist thermal denaturation and maintain structural integrity under physiological conditions. Sequence variations across species primarily occur in loop regions or surface positions, preserving the core's apolar character essential for stability.

Heme Prosthetic Group and Binding Mechanism

The heme prosthetic group of myoglobin is a ferroprotoporphyrin IX complex featuring a ferrous iron (Fe²⁺) ion at its center, embedded within a hydrophobic pocket formed by the globin fold. This non-covalently bound cofactor enables reversible oxygen binding, with the iron coordinated axially by the imidazole nitrogen of the proximal histidine residue (His93 in sperm whale myoglobin). The heme's porphyrin ring provides a planar scaffold that positions the iron for ligand interaction while shielding it from solvent. In the deoxy form, the Fe²⁺ adopts a high-spin (S=2) electronic configuration, remaining pentacoordinate and displaced approximately 0.4–0.6 Å out of the heme plane toward the proximal histidine. Oxygen binding at the sixth coordination site induces a transition to a low-spin (S=0) state, pulling the iron into the porphyrin plane and triggering a conformational shift in the F helix attached to His93. This structural rearrangement facilitates tight packing around the ligand, enhancing stability. The distal histidine (His64) plays a critical role in the binding mechanism by donating a hydrogen bond to the bound O₂ molecule, stabilizing the bent Fe–O–O geometry (bond angle ~120°) characteristic of oxy-myoglobin. This interaction discriminates against carbon monoxide (CO), which prefers linear binding, by imposing steric hindrance that reduces CO affinity by a factor of ~20–200 compared to free heme. Additionally, the hydrogen bond from His64 impedes auto-oxidation, the spontaneous conversion to ferric metmyoglobin (Fe³⁺), which occurs via dissociation of superoxide (O₂⁻) and renders the protein inactive for oxygen transport. Mutational studies confirm that replacing His64 increases auto-oxidation rates by 10–100 fold, underscoring its protective function. The hydrophobic environment of the pocket further minimizes solvent access, reducing protonation events that could promote oxidation.

Evolutionary Conservation

Myoglobin belongs to the globin superfamily, an ancient protein family that originated approximately 4 billion years ago as a basic structural fold for proto-oxygen binding under anaerobic primordial conditions. This superfamily predates the gene duplication events in early vertebrates that produced the α- and β-globin subunits of tetrameric hemoglobin around 500 million years ago, positioning myoglobin as a more ancestral, monomeric form within the lineage. Sequence analyses across diverse taxa, including vertebrates and invertebrates like annelids, reveal striking conservation of the core globin domain, with invariant residues at key positions such as the proximal (F8) and distal (E7) histidines essential for heme iron coordination. This homology, often exceeding 30-40% identity between mammalian species despite divergence over hundreds of millions of years, indicates profound selective constraints to maintain the three-over-three α-helical sandwich fold and oxygen-binding pocket against mutational drift. In extremophile and specialized lineages, such as Antarctic notothenioid fishes, myoglobin coding sequences show minimal variation among expressing species, with synonymous substitutions dominating non-coding regions, further evidencing purifying selection on functional exons. Similarly, fossorial mammals like moles exhibit conserved myoglobin primary structures adapted for hypoxia tolerance, prioritizing stability in low-oxygen burrows without compromising the canonical binding sites. Diving mammals, including cetaceans and pinnipeds, demonstrate convergent sequence adaptations under apnea-related selective pressures, evolving elevated net positive surface charges via lineage-specific amino acid substitutions to boost protein solubility and permit myoglobin concentrations up to tenfold higher than in terrestrial counterparts. These changes, reconstructed through ancestral protein resurrection, preserve over 80% structural overlap with basal globins while enhancing resistance to macromolecular crowding in densely packed muscle fibers during prolonged submersion. Such modifications highlight how niche-specific pressures can drive localized sequence divergence atop a highly conserved scaffold, enabling elevated oxygen storage without altering the core heme-binding apparatus.

Physiological Function

Oxygen Storage and Delivery in Muscle

Myoglobin serves as the primary oxygen storage protein in vertebrate skeletal and cardiac muscle, binding molecular oxygen reversibly to its heme prosthetic group via the equilibrium Mb + O₂ ⇌ MbO₂. This monomeric protein exhibits a hyperbolic oxygen dissociation curve, characterized by non-cooperative binding and a high affinity with a P₅₀ value of approximately 2-3 mmHg, enabling near-complete saturation at typical intracellular partial pressures of oxygen (20-40 mmHg). In contrast, hemoglobin's sigmoidal curve reflects cooperative binding among its tetrameric subunits, with a higher P₅₀ of about 26 mmHg suited for oxygen transport in blood. The hyperbolic binding kinetics follow Michaelis-Menten-like behavior, allowing myoglobin to act as an efficient oxygen reservoir that remains largely oxygenated under normoxic conditions but releases O₂ when tissue PO₂ drops during intense contraction or transient ischemia. This delivery mechanism supports sustained aerobic metabolism by providing oxygen directly to mitochondrial cytochrome c oxidase when hemoglobin dissociation alone is insufficient, particularly in fast-twitch fibers with limited vascular supply. In hypoxia-adapted species, such as diving mammals, myoglobin concentrations in muscle can reach 5-10% of cytosolic protein by mass, far exceeding levels in terrestrial counterparts, thereby amplifying storage capacity to sustain prolonged apnea. For instance, in the bottlenose whale, elevated myoglobin facilitates dives exceeding 2 hours by maintaining intracellular O₂ availability for ATP production via oxidative phosphorylation despite circulatory adjustments that prioritize vital organs. This adaptation underscores myoglobin's role in buffering oxygen deficits, with evolutionary increases in expression correlating to dive duration across pinnipeds and cetaceans.

Facilitation of Oxygen Diffusion

Myoglobin enhances intracellular oxygen transport in muscle fibers by serving as a diffusible carrier that binds O₂ near the cell membrane and releases it toward consuming sites like mitochondria, effectively increasing the oxygen flux beyond what free diffusion alone would permit under Fick's first law, where flux J=−D∂C∂xJ = -D \frac{\partial C}{\partial x} and the presence of mobile myoglobin-bound O₂ raises the effective diffusion coefficient DD. This facilitation arises because myoglobin's rapid on-off kinetics for O₂ binding—characterized by an association rate constant of approximately 1.3×107 M−1s−11.3 \times 10^7 \, \mathrm{M^{-1} s^{-1}} and dissociation rate of 10−20 s−110-20 \, \mathrm{s^{-1}} at physiological conditions—allow it to traverse the cytosol while maintaining a steeper average concentration gradient compared to unbound O₂ alone. Experimental measurements in isolated muscle preparations confirm that myoglobin's contribution elevates the apparent O₂ diffusivity by 1.5- to 3-fold, depending on saturation levels and fiber type. The abundance of myoglobin within a typical mammalian skeletal muscle fiber—reaching concentrations of 0.2-1 mM, equivalent to roughly 10^4-10^5 molecules per μm² of cross-sectional area—multiplies this facilitative effect, as the aggregate carrier capacity linearly scales with total myoglobin content per Fickian principles, enabling sustained O₂ supply to distal mitochondria during elevated demand without relying solely on extracellular gradients. Mathematical models incorporating myoglobin's diffusion coefficient (around 1.2×10−7 cm2s−11.2 \times 10^{-7} \, \mathrm{cm^2 s^{-1}}) and binding stoichiometry predict that this density prevents intracellular PO₂ drops below critical thresholds in high-oxidative fibers, with facilitation becoming most pronounced at partial desaturations (20-50% MbO₂). In ischemia-reperfusion scenarios, such as those modeled in perfused heart or skeletal muscle preparations, myoglobin-mediated shuttling accelerates O₂ redistribution upon reoxygenation, reducing the time lag for mitochondrial resupply and mitigating transient hypoxia; for instance, fluorescence-based imaging in cardiomyocytes reveals spatially resolved MbO₂ gradients that resolve faster in wild-type versus myoglobin-deficient models, underscoring its role in flux augmentation during recovery from oxygen deprivation. These observations align with biophysical assays showing myoglobin's facilitation prevents localized anoxia in fiber cores post-ischemia, though its efficacy diminishes if autoxidation to metmyoglobin exceeds 10-20% under prolonged stress.

Metabolic Roles Beyond Oxygen Transport

Myoglobin demonstrates nitrite reductase activity in its deoxygenated state, particularly under hypoxic conditions where oxygen tension is low, reducing nitrite (NO₂⁻) to nitric oxide (NO). This enzymatic function was characterized through spectroscopic assays, including stopped-flow spectrophotometry, revealing that deoxymyoglobin reduces nitrite at a rate approximately 36 times faster than deoxyhemoglobin due to its lower heme reduction potential and monomeric structure, which facilitates substrate access. Empirical measurements via chemiluminescence detection confirmed NO production rates increasing with decreasing pH and oxygen levels, mimicking physiological ischemia. The generated NO contributes to hypoxic vasodilation by activating soluble guanylate cyclase in vascular smooth muscle, thereby elevating cyclic GMP and promoting vessel relaxation to enhance blood flow and oxygen delivery to tissues. In cardiac tissue, myoglobin-dependent nitrite reduction to NO was shown in isolated perfused hearts under hypoxia, where myoglobin knockout abolished nitrite-mediated vasodilation, as quantified by pressure-flow relationships and NO-sensitive electrodes. Additionally, this NO inhibits cytochrome c oxidase in mitochondria, reducing oxygen consumption and preserving cellular viability during ischemia-reperfusion, as evidenced by respirometry assays in myoglobin-expressing cardiomyocytes versus knockouts. These roles position myoglobin as a metabolic regulator that integrates oxygen sensing with nitric oxide signaling under low-oxygen stress.

Comparative Biochemistry

Key Differences from Hemoglobin

Myoglobin and hemoglobin differ fundamentally in their oligomeric state, with myoglobin functioning as a monomeric protein comprising a single polypeptide chain and one heme prosthetic group, while hemoglobin is a heterotetramer consisting of two α and two β subunits, each bearing a heme group. This structural disparity precludes cooperative interactions in myoglobin, resulting in independent oxygen binding at its sole heme, whereas hemoglobin's subunit interfaces enable allosteric conformational shifts between tense (T) and relaxed (R) states, promoting sequential oxygen binding that enhances overall affinity after initial ligation. The oxygen dissociation curve of myoglobin is hyperbolic, indicative of non-cooperative binding and a high intrinsic affinity (P50 ≈ 2–3 mmHg), allowing efficient oxygen sequestration at low partial pressures typical of muscle interiors. Hemoglobin, by contrast, displays a sigmoidal curve due to positive cooperativity (Hill coefficient ≈ 2.8), with a lower affinity (P50 ≈ 26 mmHg) that facilitates oxygen loading in lungs and unloading in tissues. Myoglobin's oxygen affinity remains unaffected by allosteric modulators such as 2,3-bisphosphoglycerate (2,3-BPG), which binds exclusively to the deoxyhemoglobin tetramer's central cavity—formed by the β subunits—stabilizing the low-affinity T-state and shifting hemoglobin's curve rightward by up to 50% under physiological concentrations (≈5 mM in erythrocytes). Absent this binding pocket and subunit assembly, myoglobin exhibits invariant affinity across physiological pH and effector gradients, underscoring its role in stable storage rather than regulated transport.

Similarities and Shared Evolutionary Origins

Myoglobin and hemoglobin belong to the ancient globin superfamily, which includes oxygen-binding proteins distributed across bacteria, archaea, protists, plants, and animals, indicating a shared evolutionary origin predating the vertebrate-invertebrate divergence more than 800 million years ago. The common ancestor of these proteins was likely a monomeric globin similar in structure to modern myoglobin, with hemoglobin arising through subsequent gene duplication and assembly into tetrameric forms. This ancestral globin primarily functioned in oxygen scavenging or protection against reactive species, with specialized transport and storage roles evolving later in vertebrates. Both proteins share the canonical globin fold, characterized by eight alpha-helices (labeled A–H) enclosing a heme-binding pocket, a tertiary structure conserved across the superfamily to accommodate the porphyrin ring and enable reversible ligand binding. Key residues in the heme pocket, including the proximal histidine at position F8 that coordinates the iron atom axially, and the distal histidine at E7 that hydrogen-bonds to bound dioxygen, are invariant in vertebrate myoglobins and hemoglobin subunits, ensuring similar binding geometries despite functional divergence. Amino acid sequence identity between myoglobin and individual hemoglobin alpha or beta chains averages around 25%, underscoring their descent from a single primordial gene while allowing adaptations like cooperativity in hemoglobin. Phylogenetic analyses of globin genes reveal that myoglobin (encoded by the MB locus on human chromosome 22) and hemoglobin clusters (on chromosomes 11 and 16) arose from tandem duplications of an proto-globin gene in early vertebrates, with the monomeric storage function of myoglobin representing the more primitive state retained for intracellular oxygen buffering in muscle tissues. This shared heritage is evident in non-vertebrate homologs, such as annelid erythrocruorins and bacterial hemoglobins, which exhibit analogous heme coordination and fold stability, supporting a deep evolutionary conservation driven by selective pressure for oxygen homeostasis.

Role in Pathology and Diagnostics

Association with Rhabdomyolysis and Myoglobinuria

Rhabdomyolysis, characterized by the rapid dissolution of skeletal muscle fibers, results in the massive release of intracellular contents, including myoglobin, into the bloodstream, often manifesting as myoglobinuria with dark, cola-colored urine. Common precipitants include severe physical trauma, such as crush injuries; extreme muscular exertion, as in marathon running or military training; and pharmacological agents like statins, which impair muscle cell integrity and amplify damage under stress. The risk escalates with concurrent factors, such as statin use combined with intense exercise, where myoglobin efflux overwhelms renal clearance capacity. This myoglobin overload directly contributes to acute kidney injury (AKI) through nephrotoxic effects, with plasma myoglobin levels exceeding 15,000 μg/L strongly correlating with AKI onset and dialysis requirement. Histological examinations of affected kidneys reveal granular casts composed of myoglobin in distal tubules, causing mechanical obstruction, back-pressure atrophy, and impaired glomerular filtration. Empirical biopsy data confirm that these Tamm-Horsfall protein-myoglobin aggregates precipitate in acidic, concentrated urine, exacerbating ischemic tubular damage independent of hemoglobinuria. While oxidative stress and vasoconstriction play roles, tubular obstruction remains the primary causal pathway evidenced by autopsy and biopsy findings in rhabdomyolysis cases.

Clinical Biomarkers and Testing

Serum myoglobin levels are measured as an early indicator of skeletal muscle injury, particularly in rhabdomyolysis, where release from damaged myocytes precedes elevations in creatine kinase (CK). Immunoassays, including enzyme-linked immunosorbent assays (ELISA) and chemiluminescent microparticle assays, enable rapid quantification in serum or plasma, often within minutes to hours for point-of-care testing. These methods detect myoglobin concentrations typically exceeding 100-200 ng/mL as suggestive of significant muscle breakdown, though thresholds vary by assay. Compared to CK-MM, the predominant muscle isoform of creatine kinase, myoglobin demonstrates superior early sensitivity, with detectable rises within 1-3 hours post-injury versus 3-12 hours for CK. However, myoglobin's plasma half-life of 2-3 hours leads to swift normalization, even as muscle damage persists, rendering serial measurements unreliable for monitoring disease progression or resolution. CK-MM, with a half-life exceeding 36 hours, thus serves as the primary biomarker for confirming rhabdomyolysis and assessing severity, often requiring levels >5 times the upper reference limit (e.g., >1,000 U/L). Urine myoglobin testing complements serum assays by identifying myoglobinuria, confirmed via immunoassay when dipstick positive for blood but negative for red cells. Limitations of myoglobin testing include its low specificity, as elevations can occur from non-rhabdomyolytic causes like strenuous exercise or hemolysis, and its brief detectability window, which may yield false negatives if sampling is delayed beyond 6-8 hours. Alone, myoglobin lacks robust prognostic utility for outcomes such as acute kidney injury, as peak levels do not independently predict complications like dialysis need or mortality; instead, it informs initial triage but requires integration with CK trends, renal function, and clinical context. Guidelines emphasize CK over myoglobin for routine diagnostics due to these constraints.

Contributions to Oxidative Stress

Myoglobin contributes to oxidative stress through its heme iron, which under pathological conditions such as ischemia-reperfusion injury undergoes oxidation to the ferryl species (MbFe^{IV}=O), a highly reactive form capable of generating reactive oxygen species (ROS) including superoxide and hydroxyl radicals via Fenton-like reactions. This process is initiated by hydrogen peroxide or peroxynitrite, leading to heme degradation, free iron release, and subsequent lipid peroxidation, protein oxidation, and DNA damage in muscle and adjacent tissues. In myocardial ischemia-reperfusion models, myoglobin exhibits two-phase oxidation: initial formation of metmyoglobin followed by ferrylmyoglobin accumulation, which correlates with elevated ROS levels and enlarged infarct sizes as observed in isolated rat hearts and imaging studies. Ferryl myoglobin exacerbates oxidative during reperfusion by catalyzing that propagates ROS bursts, contributing to cellular in conditions like rhabdomyolysis and where myoglobinuria releases the protein systemically. Causal from 2020s models demonstrates that myoglobin-derived iron induces through iron overload and in tubular cells, independent of effects, with iron chelators like deferasirox reducing tissue by limiting ROS . Endogenous antioxidants, such as ergothioneine and nitrite-derived species, mitigate ferryl myoglobin's reactivity by reducing it back to ferric metmyoglobin, thereby attenuating ROS-mediated inflammation and necrosis in ischemic tissues. Recent in vitro and ex vivo studies confirm that while myoglobin's peroxidatic activity drives oxidative stress in inflammation-associated heme release, targeted interventions like herbal antioxidants (e.g., glycyrrhizin) suppress these pathways in diabetic and reperfusion models.

Applications in Food Science

Influence on Meat Color and Quality

Myoglobin, the primary pigment in skeletal muscle, determines the color of fresh meat through its oxygenation states: deoxymyoglobin imparts a purplish-red hue under anaerobic conditions, oxymyoglobin produces the desirable cherry-red "bloom" upon exposure to oxygen, and metmyoglobin results in an unappealing brown discoloration via oxidation. Higher myoglobin concentrations correlate with darker red meat colors, varying by species and muscle type, with beef exhibiting elevated levels compared to pork or poultry. The red liquid that seeps from raw, rare, or medium-rare steaks—often observed on cutting boards or in packaging—is commonly mistaken for blood. In fact, this exudate, known as purge, is primarily a mixture of water (approximately 75% of muscle tissue) and myoglobin, which imparts the red color due to its iron-containing heme group. This myoglobin-containing purge in medium-rare steak contributes to its characteristic "bloody" or metallic taste, arising from the iron-heme complex in undenatured myoglobin that releases an iron-like flavor when the meat is consumed (not from actual blood, which is drained during slaughter). Nearly all blood is drained from the carcass during slaughter, leaving only trace amounts in the muscle tissue. Meat quality perception is heavily influenced by this color stability, as rapid metmyoglobin formation signals spoilage to consumers despite the meat remaining microbiologically safe. For instance, browning on a prime rib roast is typically not a sign of spoilage but is caused by the oxidation of myoglobin exposed to air; beef that has turned black from oxidation is safe to eat if it shows uniform darkening without green spots, has a normal beef smell without sour or rotten odor, exhibits a dry, non-sticky texture without slime, and is within 3-5 days of refrigerated storage or properly frozen; it remains safe when cooked with minimal texture impact, but should be discarded if signs of spoilage are present. In aerobic packaging, oxygen facilitates myoglobin blooming within minutes, forming a stable oxymyoglobin layer on the surface that enhances visual appeal, whereas vacuum packaging maintains deoxymyoglobin, yielding a darker, less vibrant appearance until air exposure triggers delayed blooming. Vacuum conditions limit oxygen availability, reducing metmyoglobin accumulation and preserving color longer during storage by minimizing oxidation, though reoxygenation post-opening can still produce bloom if myoglobin remains functional. This packaging differential affects quality by extending shelf life in vacuum (up to 23-36 days depending on conditions) versus aerobic systems, where surface discoloration accelerates due to unchecked myoglobin autoxidation. Myoglobin stability, assessed via spectrophotometry measuring absorbance at wavelengths like 525 nm for oxymyoglobin and 630 nm for metmyoglobin, declines at lower pH values typical of postmortem muscle (e.g., 5.3-5.6 in pale, soft, exudative meat), promoting protein denaturation and hastening brown pigment formation. At pH below 5.6, metmyoglobin solubility decreases and thermal denaturation increases, compromising color retention even under controlled packaging, while higher pH (above 6.0) enhances redox stability and delays oxidation. These pH-driven changes indirectly influence perceived texture through associated protein alterations, such as increased drip loss from denatured sarcoplasmic proteins, though myoglobin's primary impact remains visual.

Processing Effects and Culinary Implications

Heat denaturation of myoglobin in meat occurs progressively, beginning at approximately 55°C for certain forms like metmyoglobin under acidic conditions (pH 5), with complete denaturation typically achieved by 80°C, resulting in the release of the heme prosthetic group and a shift in meat color from red or pink to brown due to oxidation and structural unfolding of the protein. This color transition is evident in steak cooking, where rare or medium-rare doneness preserves red oxymyoglobin in the interior and red juices, while well-done cooking produces a uniform brown appearance as myoglobin denatures and oxidizes. This is influenced by factors such as the initial redox state of myoglobin (e.g., oxymyoglobin denatures to brown more readily than deoxymyoglobin, which may retain redness up to 65°C), pH (higher pH delays denaturation and preserves red hues), and cooking endpoint temperature, with lower temperatures (e.g., 55°C) yielding pinker interiors in deoxymyoglobin-dominant samples. In chemical processing like curing, nitrates are reduced to nitrites, which react with myoglobin to form nitrosylmyoglobin, a bright red pigment that, upon heating, converts to the heat-stable nitrosohemochrome, maintaining a characteristic pink-red color in processed meats even after cooking to temperatures exceeding 70°C. This stabilization prevents the typical browning from denaturation, enhancing visual stability under vacuum or light exposure, though the pigment fades in air. Culinary implications include altered sensory perception of doneness, where denatured myoglobin contributes to the opaque, browned appearance signaling "cooked" status, influencing consumer preferences for rarer preparations that retain native red oxymyoglobin for juiciness and flavor associations. In medium-rare steak, undenatured myoglobin imparts a metallic or iron-like flavor often described as "bloody" or addictive, as many find this taste highly appealing when combined with rich umami from amino acids, juicy texture from retained moisture, fats, and savory compounds produced by the Maillard reaction. In cured products, the persistent pink hue supports uniform aesthetics in items like sausages or hams, but requires precise control of nitrite levels to avoid over-stabilization mimicking undercooking. These effects underscore myoglobin's role in balancing food safety endpoints with desirable texture and color retention during grilling, roasting, or smoking.

Synthetic and Engineered Variants

Design of Myoglobin Analogues

The design of synthetic myoglobin analogues via chemical synthesis focuses on replicating the heme group's reversible dioxygen-binding capability, particularly the steric and electronic environment of the distal pocket that stabilizes the bound O₂ and prevents unwanted side reactions. Early efforts with simple iron porphyrins failed to achieve this, as exposure to O₂ led to rapid autooxidation and formation of stable μ-oxo diiron(III) dimers, mimicking the irreversible reactivity observed outside the protein matrix. This dimerization arises from nucleophilic attack by a second Fe(II) center on the bound O₂, forming a bridged peroxide intermediate that disproportionates, thereby challenging the creation of functional models without protein encapsulation. To overcome these obstacles, researchers engineered porphyrins with asymmetric steric bulk to enforce a protected binding pocket, directing end-on O₂ coordination akin to native myoglobin and hindering intermolecular dimerization. A landmark achievement was the 1975 development of "picket fence" porphyrins by James P. Collman and colleagues, utilizing meso-tetrakis(α,α,α,α-o-pivalamidophenyl)porphyrin iron(II), where four pendant pivalamido "pickets" on one porphyrin face create a cleft deep enough to sequester the O₂ ligand while allowing access via the opposite face for a proximal imidazole base. This architecture not only prevented dimerization but enabled reversible O₂ binding at ambient temperature in non-aqueous solvents, with the oxy-adduct displaying bent Fe-O-O geometry and ν(O-O) stretching frequency around 1130 cm⁻¹, closely resembling oxy-myoglobin values. Subsequent refinements, such as cobalt-substituted picket fence variants, demonstrated comparable O₂ affinities to cobalt-reconstituted myoglobin, underscoring the model's fidelity in emulating proximal histidine tuning of ligand affinity. These synthetic constructs provided foundational insights into heme-O₂ chemistry, including the role of distal steric constraints in discriminating against CO versus O₂ binding, with discrimination factors (M values) tunable over orders of magnitude through peripheral modifications. Despite successes, challenges persist in achieving aqueous solubility and stability under physiological conditions without irreversible oxidation, limiting direct biomedical translation but advancing fundamental understanding of oxygen carrier design.

Plant-Based and Recombinant Production

Recombinant production of myoglobin typically involves expression in microbial hosts such as Escherichia coli or yeast species like Saccharomyces cerevisiae. In E. coli, engineered strains facilitate heme cofactor incorporation, enabling yields of holomyoglobin (heme-bound form) through optimized expression vectors and co-expression of heme biosynthesis pathways, though specific titers for myoglobin range from milligrams per liter depending on conditions. In yeast, bovine myoglobin expression reached nearly 1% of total extractable protein, confirming functional heme binding via spectroscopic analysis. Purification often includes affinity chromatography and size-exclusion steps to isolate apo- (heme-free) or holo-forms, with protocols adapted for mutants or high-purity needs. Plant-based production offers an alternative platform leveraging transient expression systems in species like Nicotiana benthamiana for scalable, heme-integrated myoglobin synthesis. A 2020 study demonstrated human myoglobin production via Agrobacterium-mediated delivery of a tobacco mosaic virus-based vector (pJL-TRBO), targeting cytosolic or chloroplastic localization without external heme supplementation, as endogenous plant heme suffices for holoprotein assembly. Yields varied by infiltration method: agroinfiltration achieved approximately 210 mg/kg fresh leaf weight, while agrospray yielded 60–80 mg/kg, with the latter scalable for field application. Purification from plant extracts involved heat denaturation at 60°C for 10 minutes to remove heat-labile contaminants, followed by ammonium sulfate precipitation at 2.28 M and anion-exchange chromatography on HiTrap Q-Sepharose, attaining ~65% purity pre-chromatography and spectral ratios (A540/A274) up to 0.389 indicative of functional holo-myoglobin. The plant-derived myoglobin exhibited native-like ligand binding (e.g., oxygen, carbon monoxide), autoxidation rates of 0.046 ± 0.004 h⁻¹, and thermal stability with melting temperatures of 73.5°C (oxy-form) and 78.9°C (carboxy-form), validating its utility as a heme-protein source. This approach highlights plants' potential for cost-effective production of oxygen-binding proteins, bypassing microbial heme limitations.

Potential Therapeutic Uses

Engineered variants of myoglobin have been explored for their potential to serve as components in hemoglobin-based oxygen carriers (HBOCs), leveraging the protein's monomeric heme-binding structure as a model for designing stable, cell-free oxygen transport systems. Studies have demonstrated that mutations enhancing heme retention in recombinant myoglobin could inform the development of safer HBOCs by reducing dissociation and associated oxidative damage, though clinical translation remains limited by broader HBOC challenges such as nitric oxide scavenging leading to vasoconstriction and hypertension. Gene therapy approaches involving myoglobin overexpression have shown promise in mitigating ischemia-reperfusion injury by facilitating intracellular oxygen storage and ATP preservation, as evidenced in rat models where hepatic transduction with myoglobin cDNA reduced injury markers and improved energy homeostasis post-ischemia. However, skeletal muscle-specific overexpression in transgenic mice has paradoxically impaired perfusion recovery and angiogenesis following hind-limb ischemia, potentially due to altered oxygen gradients disrupting vascular remodeling signals. These conflicting outcomes highlight the context-dependent effects of myoglobin modulation, with protective roles in acute hepatic settings but inhibitory impacts on chronic ischemic adaptation in striated muscle. Targeted delivery of oxygen-bound myoglobin has been proposed to enhance radiotherapy outcomes in hypoxic tumors by increasing local oxygenation and radiosensitivity, with in vitro and xenograft studies indicating improved tumor control when myoglobin is conjugated to tumor-homing peptides. Despite these preclinical advances, no myoglobin-derived therapeutics have progressed to human trials, underscoring persistent concerns over immunogenicity, heme instability, and off-target effects in vivo.

Recent Advances and Research Directions

Studies on Expression Regulation

Expression of the myoglobin (MB) gene in skeletal muscle is primarily regulated at the transcriptional level by hypoxia-inducible factors (HIFs), which respond to oxygen deprivation by stabilizing HIF-1α and promoting MB transcription as an adaptive mechanism to enhance oxygen storage and diffusion. Studies demonstrate that hypoxia alone induces modest increases in myoglobin mRNA, but synergistic effects with muscle contraction—via elevated intracellular calcium and calcineurin activation—significantly amplify MB expression, leading to up to 4-fold elevations in protein levels under combined stimuli. This regulation involves hypoxia-responsive elements in the MB promoter, though the exact HIF-binding affinity remains debated, with some evidence suggesting indirect modulation through calcium flux reprogramming rather than direct HIF transactivation in all muscle types. In non-muscle tissues, such as epithelial cells and renal carcinoma lines, hypoxia similarly upregulates myoglobin via HIF-independent pathways in some cases, with increases up to 62-fold observed in vitro, potentially linking expression to prolyl-hydroxylase modulation and altered HIF-1α stability. Comprehensive reviews highlight that MB expression is also influenced by muscle fiber type specification factors, with oxidative slow-twitch fibers exhibiting baseline higher levels due to sustained calcineurin signaling, while fast-twitch fibers require chronic hypoxic training for induction. Interventional studies targeting MB overexpression have explored therapeutic potential in age-related muscle decline. In aged mice (24 months), NOR-1 (neuron-derived orphan receptor 1) overexpression via gene delivery elevated myoglobin levels through PERM1 (PPARGC1- and ERR-induced regulator, muscle 1) mediation, resulting in enhanced mitochondrial respiration, fatigue resistance, and endurance performance comparable to young controls. This approach counters sarcopenic reductions in oxidative capacity, where baseline myoglobin declines correlate with diminished oxygen handling, though human translation remains limited by delivery efficiency and off-target effects. Conversely, transgenic myoglobin overexpression in ischemic models has shown mixed outcomes, sometimes impairing reperfusion angiogenesis, underscoring context-specific regulatory feedback.

Insights into Heme Protein Pathophysiology

Myoglobin and hemoglobin, as major heme-containing proteins, can exacerbate oxidative stress in various disease states by facilitating the generation of reactive oxygen species (ROS) through heme iron-mediated catalysis. Under conditions of cellular stress, such as ischemia-reperfusion injury or rhabdomyolysis, the release of free heme from these proteins promotes Fenton-like reactions, leading to hydroxyl radical formation and subsequent lipid peroxidation, protein oxidation, and DNA damage. This mechanism underlies tissue injury, particularly in the kidney, where myoglobinuric damage disrupts mitochondrial function and uncouples oxidative phosphorylation, amplifying ROS production and cellular dysfunction. In hemolytic disorders or hypoxic stress, hemoglobin similarly contributes by oxidizing to methemoglobin, releasing ferryl heme species that propagate oxidative cascades, independent of oxygen-binding roles. These heme proteins' involvement in ROS dynamics extends to chronic stress responses, where dysregulated nitric oxide (NO) interactions further intensify pathophysiology. Myoglobin's peroxidase-like activity, while potentially scavenging peroxynitrite under normoxia, shifts to pro-oxidant behavior during heme destabilization, fostering nitro-oxidative stress in affected tissues. Recent analyses confirm that such mechanisms do not correlate with reduced oxidative defense in hemoglobin/myoglobin-deficient models but rather highlight heme release as a primary driver of damage in wild-type systems under acute stress. In diabetic models, hyperglycemia induces non-enzymatic glycation of myoglobin, forming advanced glycation end products (AGEs) that alter heme pocket conformation and impair oxygen storage, thereby reinforcing insulin resistance via impaired muscle oxygenation and metabolic feedback loops. Site-specific glycation, particularly with reducing sugars like glucose or melibiose, generates stable adducts such as methylglyoxal-derived hydroimidazolone, which disrupt iron coordination and enhance auto-oxidation rates, linking protein modification to elevated ROS and vascular complications. Elevated plasma myoglobin levels in type 2 diabetes correlate mechanistically with glycation-induced renal tubular injury, where modified myoglobin exacerbates glomerular hyperfiltration and fibrosis through sustained oxidative and inflammatory signaling. These processes illustrate a causal pathway from glycation to heme protein dysfunction, distinct from hemoglobin's predominant vascular effects.

Emerging Biomedical and Industrial Applications

Myoglobin's species-specific amino acid sequences enable its use as a biomarker in the food industry for authenticating meat origins and detecting adulteration, particularly through mass spectrometry targeting unique peptides derived from myoglobin isoforms across species such as beef, pork, horse, and lamb. Multiple reaction monitoring (MRM) assays have achieved detection limits as low as 0.5% contaminant levels in processed meats, facilitating rapid identification even after cooking or processing. This approach leverages myoglobin's thermal stability and solubility, providing a reliable alternative to DNA-based methods for traceability in commercial supply chains. In biomedical research, myoglobin is investigated as a targeted oxygen carrier to alleviate hypoxia in pathological tissues, with preclinical studies demonstrating its potential to deliver oxygen directly to hypoxic cancer cells, thereby enhancing the efficacy of radiation or chemotherapeutic interventions. For example, conjugation of myoglobin to tumor-targeting moieties has shown increased intracellular oxygenation in vitro, reducing tumor resistance to oxidative therapies. However, translation to clinical hemoglobin-based oxygen carriers (HBOCs), which share mechanistic similarities with myoglobin in heme-mediated oxygen binding, has been hindered by adverse effects including vasoconstriction from nitric oxide scavenging, oxidative stress, and elevated myocardial infarction risk observed in phase III trials of products like Hemopure and Hemospan. These failures highlight inherent challenges in free heme proteins, such as auto-oxidation and lipid peroxidation, necessitating advanced protein engineering for safer myoglobin variants, though none have yet progressed beyond preclinical stages as of 2025.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK544256/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC2912754/
  3. https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=MB
  4. https://academic.oup.com/nar/article/12/7/3235/1088083
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC5980623/
  6. https://www.nobelprize.org/prizes/chemistry/1962/kendrew/facts/
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC3391710/
  8. https://journals.physiology.org/doi/10.1152/physiologyonline.2000.15.5.269
  9. https://journals.physiology.org/doi/10.1152/jappl.2000.88.4.1467
  10. https://wellcomecollection.org/works/x2qhpee4
  11. https://journals.biologists.com/jeb/article/213/16/2734/9845/Unmasking-the-Janus-face-of-myoglobin-in-health
  12. https://www.nobelprize.org/uploads/2018/06/theorell-lecture.pdf
  13. https://www.nature.com/articles/162496b0
  14. https://royalsocietypublishing.org/doi/10.1098/rspa.1957.0002
  15. https://royalsocietypublishing.org/doi/10.1098/rspa.1958.0145
  16. https://onlinelibrary.wiley.com/iucr/itc/Fa/ch1o2v0001/
  17. https://pubmed.ncbi.nlm.nih.gov/19712775/
  18. https://www.nature.com/articles/milecrystal12
  19. https://www.uniprot.org/uniprotkb/P02144/entry
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC3970890/
  21. https://www.biorxiv.org/content/10.1101/2022.07.12.499700v1.full.pdf
  22. https://www.nature.com/articles/s41598-019-47317-y
  23. https://pubs.acs.org/doi/10.1021/acsomega.8b03218
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC2222724/
  25. https://www.researchgate.net/figure/Folding-structure-units-in-myoglobin_fig1_330331419
  26. https://www.nature.com/articles/s41598-018-34984-6
  27. https://www.sciencedirect.com/science/article/pii/S0021925819783082
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC2838306/
  29. https://pubmed.ncbi.nlm.nih.gov/3057383/
  30. https://febs.onlinelibrary.wiley.com/doi/10.1046/j.1432-1327.2000.01685.x
  31. https://www.sciencedirect.com/science/article/pii/S1631069108002278
  32. https://pharmaceuticalintelligence.com/2015/01/19/life-on-earth-is-traced-to-oxygen-binding/
  33. https://academic.oup.com/gbe/article/12/10/1719/5864725
  34. https://www.ks.uiuc.edu/Training/CaseStudies/pdfs/myoglobin.pdf
  35. https://pubmed.ncbi.nlm.nih.gov/9284559/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC8205494/
  37. https://pubmed.ncbi.nlm.nih.gov/33181325/
  38. https://www.sciencedirect.com/science/article/pii/S2589004221008889
  39. https://chem.libretexts.org/Courses/Earlham_College/CHEM_361%253A_Inorganic_Chemistry_%28Watson%29/07%253A_Bioinorganic_Chemistry/7.03%253A_Overview_of_Hemoglobin_and_Myoglobin/7.3.02%253A_Oxygen__Transport__by__the_Proteins__Myoglobin_and__Hemoglobin
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC8821315/
  41. https://pubmed.ncbi.nlm.nih.gov/25987728/
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC8374505/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC6237822/
  44. https://pubmed.ncbi.nlm.nih.gov/20675540/
  45. https://www.sciencedirect.com/science/article/pii/S0006349500768615
  46. https://pubmed.ncbi.nlm.nih.gov/9889930/
  47. https://www.researchgate.net/publication/51629635_Facilitated_Diffusion_of_Myoglobin_and_Creatine_Kinase_and_Reaction-Diffusion_Constraints_of_Aerobic_Metabolism_Under_Steady_State_Conditions_in_Skeletal_Muscle
  48. https://www.ahajournals.org/doi/10.1161/01.res.0000260171.52224.6b
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC2481313/
  50. https://www.ahajournals.org/doi/10.1161/circulationaha.111.087155
  51. https://www.pnas.org/doi/10.1073/pnas.0801336105
  52. https://ashpublications.org/blood/article/112/7/2636/24698/The-functional-nitrite-reductase-activity-of-the
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC5326564/
  54. https://www.purdue.edu/postlab/wp-content/uploads/PHRM836/l03_protein-structure-function-relationship_-allostery-and-cooperativity.pdf
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC3543078/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC8259614/
  57. https://pubmed.ncbi.nlm.nih.gov/9350982/
  58. https://perspectivesinmedicine.cshlp.org/content/2/12/a011627.full.pdf
  59. https://www.ncbi.nlm.nih.gov/books/NBK448168/
  60. https://my.clevelandclinic.org/health/diseases/21184-rhabdomyolysis
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC5853001/
  62. https://www.dovepress.com/a-narrative-review-of-statin-induced-rhabdomyolysis-molecular-mechanis-peer-reviewed-fulltext-article-DHPS
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC4056317/
  64. https://www.ajkd.org/article/S0272-6386%2818%2930549-3/fulltext
  65. https://www.sciencedirect.com/science/article/pii/S2468024922017910
  66. https://karger.com/kbr/article/40/5/520/185617/Molecular-Mechanisms-and-Novel-Therapeutic
  67. https://www.ncbi.nlm.nih.gov/books/NBK470441/
  68. https://www.accessdata.fda.gov/cdrh_docs/reviews/K042924.pdf
  69. https://pubmed.ncbi.nlm.nih.gov/8189324/
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC4437836/
  71. https://emedicine.medscape.com/article/1007814-workup
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC8463647/
  73. https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2025.1543455/full
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC11142982/
  75. https://elifesciences.org/articles/85633
  76. https://pubmed.ncbi.nlm.nih.gov/23190143/
  77. https://www.canr.msu.edu/news/the_color_of_meat_depends_on_myoglobin_part_1
  78. http://www.fsis.usda.gov/food-safety/safe-food-handling-and-preparation/food-safety-basics/water-meat-poultry
  79. https://meatscience.org/docs/default-source/publications-resources/hot-topics/2012_12_meat_clr_guide.pdf
  80. http://www.fsis.usda.gov/food-safety/safe-food-handling-and-preparation/food-safety-basics/color-meat-and-poultry
  81. https://www.foodsafety.gov/food-safety-charts/cold-food-storage-charts
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC4092886/
  83. https://meatscience.org/docs/default-source/publications-resources/rmc/1983/comparison-of-modified-atmosphere-versus-vacuum-packaging-to-extend-the-shelf-life-of-retail-fresh-meat-cuts.pdf
  84. http://foodandfeed.fins.uns.ac.rs/uploads/Magazines/magazine_120/Effect-of-specific-packaging-conditions-on-myoglobin-and-meat-color.pdf
  85. https://www.researchgate.net/publication/227885954_Krzywicki_Revisited_Equations_for_Spectrophotometric_Determination_of_Myoglobin_Redox_Forms_in_Aqueous_Meat_Extracts
  86. https://www.sciencedirect.com/science/article/abs/pii/S0309174001002157
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC8357901/
  88. https://www.iastatedigitalpress.com/mmb/article/id/16919/
  89. https://ift.onlinelibrary.wiley.com/doi/10.1111/j.1365-2621.1999.tb15925.x
  90. https://newprairiepress.org/cgi/viewcontent.cgi?article=1816&context=kaesrr
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC9654915/
  92. https://www.provisioneronline.com/articles/91144-understanding-the-cured-meat-reaction-1
  93. https://www.iastatedigitalpress.com/mmb/article/id/12473/
  94. https://blog.thermoworks.com/coming-heat-effects-muscle-fibers-meat/
  95. https://www.sciencedirect.com/science/article/pii/S2665927123000382
  96. https://pubs.acs.org/doi/10.1021/cr0206059
  97. https://pmc.ncbi.nlm.nih.gov/articles/PMC5097671/
  98. https://pubs.acs.org/doi/10.1021/ja00839a026
  99. https://suslick.scs.illinois.edu/documents/jacs782761.pdf
  100. https://pubs.acs.org/doi/10.1021/acs.biochem.8b00242
  101. https://pubmed.ncbi.nlm.nih.gov/2659586/
  102. https://pubmed.ncbi.nlm.nih.gov/12651126/
  103. https://www.nature.com/articles/s41598-020-57565-y
  104. https://www.jbc.org/article/S0021-9258%2820%2957740-5/fulltext
  105. https://pmc.ncbi.nlm.nih.gov/articles/PMC11826291/
  106. https://pubmed.ncbi.nlm.nih.gov/12788661/
  107. https://pmc.ncbi.nlm.nih.gov/articles/PMC3152376/
  108. https://ajp.amjpathol.org/article/S0002-9440%2813%2900590-7/fulltext
  109. https://www.sciencedirect.com/science/article/pii/S2589004220303436
  110. https://www.nature.com/articles/s12276-024-01323-x
  111. https://pubmed.ncbi.nlm.nih.gov/19005161/
  112. https://journals.physiology.org/doi/full/10.1152/ajpcell.00002.2009
  113. https://academic.oup.com/hmg/article/23/2/479/663352
  114. https://www.sciencedirect.com/science/article/abs/pii/S0014480013001068
  115. https://www.researchgate.net/publication/45440411_Regulation_of_myoglobin_expression
  116. https://pmc.ncbi.nlm.nih.gov/articles/PMC12000796/
  117. https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.202500375R
  118. https://www.sciencedirect.com/science/article/pii/S0002944013005907
  119. https://pmc.ncbi.nlm.nih.gov/articles/PMC11893434/
  120. https://www.sciencedirect.com/science/article/pii/S0925443909001367
  121. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.732190/full
  122. https://journals.biologists.com/jeb/article/221/5/jeb162503/20390/The-loss-of-hemoglobin-and-myoglobin-does-not
  123. https://www.nature.com/articles/s41598-022-25299-8
  124. https://pmc.ncbi.nlm.nih.gov/articles/PMC9655033/
  125. https://onlinelibrary.wiley.com/doi/10.1111/1753-0407.13508
  126. https://pubmed.ncbi.nlm.nih.gov/26366801/
  127. https://www.sciencedirect.com/science/article/abs/pii/S0889157523002235
  128. https://pubmed.ncbi.nlm.nih.gov/38970962/
  129. https://pmc.ncbi.nlm.nih.gov/articles/PMC9962799/
  130. https://www.mdpi.com/1422-0067/26/19/9775
Add your contribution
Related Hubs
User Avatar
No comments yet.